Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO6806127 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part 1: Single Ascending Dose (SAD) | EXPERIMENTAL | Adaptive model per protocol |
| Part 2: Food Effect (FE) | EXPERIMENTAL | Fasted versus Fed |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Matching placebo, administered orally with approximately 240 mL of buffer |
| RO6806127 | DRUG | Administered orally with approximately 240 mL of buffer |
Inclusion Criteria: * Healthy male participants aged 18 to 45 years, inclusive * A BMI between 18 to 30 kg/m2, inclusive * Agreement to use highly effective contraception Exclusion Criteria: * Clinically significant abnormalities in laboratory test results * History of any clinically significant ...
RO6806127 is an investigational small molecule being studied in healthy volunteers. It is not approved for any disease and is in early clinical development. The only completed trial evaluated the drug in healthy male participants to assess its safety and tolerability.
The molecular target of RO6806127 has not been disclosed. It is a small molecule modality, but its specific biological target is not publicly available from the clinical trial information.
RO6806127 is being developed by Roche Holding AG, which trades on the OTC market under the ticker RHHBY. The company sponsored the Phase 1 clinical trial of this investigational small molecule.
RO6806127 is in Phase 1 clinical development. The single Phase 1 study, NCT02196636, has been completed. The drug remains investigational and has not received FDA approval.
RO6806127 has one completed clinical trial, NCT02196636, titled 'A Phase 1 Study of RO6806127 in Healthy Male Volunteers.' This randomized, double-blind, controlled study enrolled 37 healthy male participants aged 18 years and older in the United States.
No alternative names for RO6806127 have been disclosed. The drug is identified solely by its code name RO6806127 in clinical trial records, and no other names or aliases are associated with it.